… were developed by Pfizer-BioNTech, Moderna, and Johnson & Johnson. Pfizer-BioNTech
and Moderna developed mRNA vaccines targeting the surface protein of SARS-CoV-2. …

… This systematic review showed that old individuals (>65 years) produce lower anti-SARS-CoV-2
antibody levels and are more likely to be low- or non-responders to Pfizer-BioNTech …

… As previously mentioned in this work, both SARS-CoV-1 and SARS-CoV-2 utilize the host
cell ACE2 receptor binding with the S protein, while MERS-CoV uses DPP4. At the cell surface…

… -based SARS-CoV-2 vaccine BNT162b2 (Pfizer-BioNTech) … SARS-CoV-2 IgG against
the Spike glycoprotein using an approved anti-SARS-CoV-2 IgG CLIA (LIAISON ® SARS-CoV…

… severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) … based SARS-CoV-2
vaccine BNT162b2 (Pfizer-BioNTech). Antibody responses were evaluated with an anti-SARS-CoV…

Data on effectiveness of the BioNTech/Pfizer COVID-19 vaccine in real-world settings are
limited. In a study of 6,423 healthcare workers in Treviso Province, Italy, we estimated that, …

… the kinetics of serum total anti-SARS-CoV-2 antibodies in a cohort of healthcare workers
who underwent voluntary administration of Pfizer-BioNTech COVID-19 mRNA-based vaccine. …

… the first injection of the SARS‐CoV‐2 Pfizer‐BioNTech mRNA. … SARS‐CoV‐2 PCR test and
serology were negative. Viral … SS induced by SARS‐CoV‐2 Pfizer‐BioNTech mRNA vaccine. …

… lower readings post first dose than Pfizer–BioNTech recipients, with and without previous …
0.001 versus Pfizer–BioNTech). Antibody responses >21 days post second Pfizer vaccination …

… mRNA BNT162b2, developed and manufactured by Pfizer-BioNTech, was one of the first
FDA-… This study strengthens the evidence that the Pfizer-BioNTech vaccination is effective in …